Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms.

Amer M ZeidanKate PerepezkoTehseen SalimiTerri WashingtonRobert S Epstein

Published in: Therapeutic advances in hematology (2024)

Survey results suggest very little/no impact on regular daily activities and improved QOL with oral DEC-C relative to IV/SC HMAs, highlighting the potential for oral DEC-C to reduce the treatment burden associated with parenteral HMA therapy.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
prognostic factors
risk assessment
combination therapy
human health
climate change
bone marrow
patient reported outcomes
replacement therapy